13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)

Page 6 of 10

Page 6 of 10 – SEC Filing


Schedule 13D

ITEM 1. SECURITY AND ISSUER

The class of equity security to which this statement on Schedule 13D relates is the
Common Stock, par value $0.001 per share (the Common Stock) of Acorda Therapeutics, Inc. (the Issuer), a Delaware corporation. The address of the principal executive offices of the Issuer is 420 Saw Mill River Road, Ardsley,
NY 10502.

Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

ITEM 2. IDENTITY AND BACKGROUND

(a) The persons filing this Schedule 13D (collectively, the Reporting
Persons) are:

1. Scopia Capital Management LP (Scopia Capital)
2. Scopia Management, Inc. (Scopia Management)
3. Matthew Sirovich
4. Jeremy Mindich

(b) The business address or address of its principal office, as applicable, of the Reporting
Persons is:

152 West 57th St., 33rd Floor

New York, NY
10019

(c) Each of the Reporting Persons is engaged in the business of investing. Scopia Capitals principal business is serving as investment
manager to certain private investment funds and a certain managed account (collectively, the Investment Vehicles). Scopia Managements principal business is serving as the general partner of Scopia Capital. The principal business of
each of Messrs. Sirovich and Mindich is serving as a Managing Director of Scopia Management.

(d) and (e) During the past five years, none of the
Reporting Persons nor any of the Investment Vehicles has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.

(f) The citizenship with respect to a natural person or state of organization with respect to an entity, as
applicable, of the Reporting Persons is as follows:

1. Scopia Capital Delaware
2. Scopia Management New York
3. Matthew Sirovich United States
4. Jeremy Mindich United States
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The aggregate purchase price of the shares of Common
Stock directly held by the Investment Vehicles reported herein was $178,109,588. The shares of Common Stock directly held by the Investment Vehicles were purchased with the working capital of the Investment Vehicles (which may, at any given time,
include margin loans made by brokerage firms in the ordinary course of business). All shares of Common Stock reported herein were purchased in open market transactions through a broker.

Follow Acorda Therapeutics Inc. (NASDAQ:ACOR)

Page 6 of 10